Phaseline

Targets › HA1

HA1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: the race on HA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Fred Hutchinson Cancer CenterCD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (HA-1 T TCR T Cel
HA-1 TCR-engineered T cell therapy targeting HA-1 antigen on leukemia cells
HA1Phase 1Juvenile Myelomonocytic LeukemiaOct 2027

Conditions

Juvenile Myelomonocytic Leukemia (1)

Modalities

other (1)

Companies

Fred Hutchinson Cancer Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.